Chapter 29 — Diabetes Pharmacology — Module 7 — Special Clinical Contexts in Diabetes Pharmacology
1. A 66-year-old man with type 2 diabetes mellitus (T2DM) has both established atherosclerotic cardiovascular disease (ASCVD) after a prior myocardial infarction and symptomatic heart failure with reduced ejection fraction. He is already on metformin. Integrating the distinct benefits of the two evidence-based classes, which add-on strategy provides the most complete cardiovascular protection?
A) Add only a glucagon-like peptide-1 receptor (GLP-1R) agonist, since it covers both atherosclerotic and heart failure endpoints
B) Add both a GLP-1R agonist and a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, because the GLP-1R agonist reduces atherosclerotic events while the SGLT-2 inhibitor reduces cardiovascular death and heart failure hospitalization
C) Add only an SGLT-2 inhibitor, since it covers both atherosclerotic and heart failure endpoints
D) Add a dipeptidyl peptidase-4 (DPP-4) inhibitor, which addresses both atherosclerotic and heart failure risk
E) Add a sulfonylurea to intensify glycemic control, which will address both complications
ANSWER: B
Rationale:
When ASCVD and heart failure coexist, combining a GLP-1R agonist with an SGLT-2 inhibitor provides dual-pathway protection: the GLP-1R agonist reduces atherosclerotic events (non-fatal myocardial infarction and stroke), while the SGLT-2 inhibitor reduces cardiovascular death and heart failure hospitalization.
Option A: Option A is incorrect because GLP-1R agonists do not provide the dominant heart failure benefit that SGLT-2 inhibitors do.
Option C: Option C is incorrect because SGLT-2 inhibitors do not provide the dominant atherosclerotic event reduction that GLP-1R agonists do.
Option D: Option D is incorrect because DPP-4 inhibitors are cardiovascular-neutral and one agent in the class increases heart failure hospitalization.
Option E: Option E is incorrect because intensified glycemic control with a sulfonylurea does not reduce these cardiovascular endpoints and adds hypoglycemia risk.
2. A 70-year-old woman with T2DM and established ASCVD presents with worsening dyspnea, peripheral edema, and a recent heart failure hospitalization; her atherosclerotic disease is stable. She is on metformin and needs a second agent. Applying the principle that agent choice should match the dominant clinical phenotype, which add-on is the most appropriate next step?
A) An SGLT-2 inhibitor, because the dominant problem is heart failure, where SGLT-2 inhibitors reduce cardiovascular death and heart failure hospitalization
B) A GLP-1R agonist, because every patient with established ASCVD should receive a GLP-1R agonist before any other class
C) Pioglitazone, because it improves insulin sensitivity and is well suited to heart failure
D) Saxagliptin, because DPP-4 inhibitors are preferred when heart failure dominates
E) A long-acting sulfonylurea, because tighter glycemic control will resolve the heart failure
ANSWER: A
Rationale:
When the dominant clinical phenotype is heart failure, an SGLT-2 inhibitor should be prioritized because it reduces cardiovascular death and heart failure hospitalization; matching the agent to the most pressing complication is the core sequencing principle.
Option B: Option B is incorrect because, although a GLP-1R agonist is valuable for atherosclerotic risk, the more pressing problem here is heart failure, where SGLT-2 inhibitors provide the dominant benefit.
Option C: Option C is incorrect because pioglitazone causes fluid retention and worsens heart failure.
Option D: Option D is incorrect because saxagliptin increases heart failure hospitalization and is contraindicated in this phenotype.
Option E: Option E is incorrect because sulfonylureas do not improve heart failure outcomes and add hypoglycemia risk.
3. A patient with T2DM and diabetic kidney disease is already on a maximally tolerated angiotensin-converting enzyme (ACE) inhibitor. The nephrologist adds an SGLT-2 inhibitor. Integrating the hemodynamic actions of the two agents, why is this combination expected to produce additive nephroprotection rather than redundant effect?
A) Both agents dilate the efferent arteriole, doubling the reduction in glomerular pressure
B) Both agents constrict the afferent arteriole, so their effects simply add at the same site
C) The ACE inhibitor raises intraglomerular pressure while the SGLT-2 inhibitor lowers it, producing a net neutral effect
D) The ACE inhibitor lowers intraglomerular pressure by dilating the efferent arteriole, while the SGLT-2 inhibitor lowers it by constricting the afferent arteriole through tubuloglomerular feedback, so the two act at different nodes of the same pressure circuit
E) The two agents share an identical mechanism, so combining them offers no additional benefit
ANSWER: D
Rationale:
The ACE inhibitor reduces intraglomerular pressure by dilating the efferent arteriole, while the SGLT-2 inhibitor reduces it by constricting the afferent arteriole through tubuloglomerular feedback; because they act at different nodes of the same glomerular pressure circuit, their effects are additive, as confirmed when SGLT-2 inhibition reduced renal events on top of background RAAS blockade.
Option A: Option A is incorrect because only RAAS blockade dilates the efferent arteriole; the SGLT-2 inhibitor acts at the afferent arteriole.
Option B: Option B is incorrect because the two agents act at different arterioles, not the same site.
Option C: Option C is incorrect because both agents lower intraglomerular pressure rather than opposing one another.
Option E: Option E is incorrect because the mechanisms are distinct, which is precisely why the benefit is additive.
4. A patient with T2DM and diabetic kidney disease has persistent albuminuria despite a maximally tolerated angiotensin receptor blocker (ARB) and an SGLT-2 inhibitor. The team considers adding finerenone for triple nephroprotective therapy. Integrating the mechanisms involved, which statement best explains the rationale and the key safety advantage of finerenone in this combination?
A) Finerenone adds a third copy of afferent arteriolar constriction, and its main advantage is a lower urinary tract infection rate than the SGLT-2 inhibitor
B) Finerenone replaces the ARB by blocking the same angiotensin II receptor more completely, reducing pill burden
C) Finerenone adds mineralocorticoid receptor blockade to the existing efferent (RAAS) and afferent (SGLT-2 inhibitor) actions, attacking residual albuminuria through a distinct pathway, and as a non-steroidal agent it carries a more favorable hyperkalemia profile than steroidal mineralocorticoid receptor antagonists
D) Finerenone works by inhibiting sodium-glucose cotransport, so it is redundant with the SGLT-2 inhibitor but cheaper
E) Finerenone provides benefit only by lowering blood glucose further, independent of any receptor mechanism
ANSWER: C
Rationale:
Finerenone adds mineralocorticoid receptor blockade to the efferent action of RAAS blockade and the afferent action of the SGLT-2 inhibitor, targeting residual albuminuria through a distinct pathway; as a non-steroidal mineralocorticoid receptor antagonist, it carries a more favorable hyperkalemia profile than steroidal agents such as spironolactone, which is the key safety advantage enabling its use on top of RAAS blockade.
Option A: Option A is incorrect because finerenone does not act at the afferent arteriole and its advantage relates to hyperkalemia, not urinary tract infections.
Option B: Option B is incorrect because finerenone blocks the mineralocorticoid receptor, not the angiotensin II receptor, and is added to rather than substituted for the ARB.
Option D: Option D is incorrect because finerenone is not an SGLT-2 inhibitor and is not redundant with one.
Option E: Option E is incorrect because finerenone acts through mineralocorticoid receptor antagonism, not through glucose lowering.
5. A patient with T2DM is taking metformin, glibenclamide (glyburide), and linagliptin. Over the past year the estimated glomerular filtration rate (eGFR) has fallen to 28 mL per minute per 1.73 m squared. Integrating the renal thresholds for each agent, which adjustment set is correct?
A) Continue all three agents unchanged, since none is affected by renal function
B) Stop linagliptin, continue metformin and glibenclamide
C) Continue glibenclamide, stop linagliptin, reduce metformin
D) Stop linagliptin and metformin, continue glibenclamide at full dose
E) Stop metformin (eGFR below 30) and stop glibenclamide (accumulating active metabolites raising hypoglycemia risk), and continue linagliptin, which needs no renal dose adjustment
ANSWER: E
Rationale:
At an eGFR of 28, metformin should be stopped because it falls below the continuation threshold of 30 and accumulation raises lactic acidosis risk; glibenclamide should be stopped because its active renally cleared metabolites accumulate and cause severe hypoglycemia; linagliptin can be continued because it requires no renal dose adjustment.
Option A: Option A is incorrect because both metformin and glibenclamide are unsafe at this eGFR.
Option B: Option B is incorrect because it stops the one safe agent (linagliptin) and continues the two unsafe ones.
Option C: Option C is incorrect because glibenclamide should be stopped, not continued, and linagliptin should be retained.
Option D: Option D is incorrect because linagliptin is safe and should be continued, whereas glibenclamide should be stopped.
6. A patient with T2DM has both diabetic kidney disease (eGFR 38 mL per minute per 1.73 m squared, persistent albuminuria) and heart failure with reduced ejection fraction. Integrating the indications across both comorbidities, which single class addresses both the renal and the cardiac problem?
A) A dipeptidyl peptidase-4 (DPP-4) inhibitor, which provides both renal and heart failure outcome benefit
B) An SGLT-2 inhibitor, which slows diabetic kidney disease progression and reduces heart failure hospitalization and cardiovascular death, addressing both comorbidities with one agent
C) A thiazolidinedione, which protects the kidney and improves heart failure outcomes
D) A sulfonylurea, which is renally protective and reduces heart failure events
E) Insulin monotherapy, which is the disease-modifying choice for both kidney disease and heart failure
ANSWER: B
Rationale:
An SGLT-2 inhibitor uniquely addresses both comorbidities: it slows diabetic kidney disease progression through afferent arteriolar pressure reduction and reduces heart failure hospitalization and cardiovascular death, so a single agent covers both the renal and cardiac indications and remains usable at this eGFR.
Option A: Option A is incorrect because DPP-4 inhibitors are cardiovascular-neutral and do not provide disease-modifying renal or heart failure benefit.
Option C: Option C is incorrect because thiazolidinediones cause fluid retention and worsen heart failure.
Option D: Option D is incorrect because sulfonylureas are neither renoprotective nor beneficial in heart failure and add hypoglycemia risk.
Option E: Option E is incorrect because insulin is not disease-modifying for kidney disease or heart failure, though it may be needed for glycemic control.
7. A patient with T2DM and New York Heart Association (NYHA) class III heart failure with reduced ejection fraction is referred for medication review. The current regimen is metformin, saxagliptin, and pioglitazone. Integrating each agent's heart failure profile, which assessment and action are correct?
A) Both saxagliptin (increased heart failure hospitalization) and pioglitazone (fluid retention, contraindicated in NYHA III-IV) are harmful here and should be replaced, ideally with an SGLT-2 inhibitor; metformin may continue if renal function permits
B) Only pioglitazone is problematic; saxagliptin is safe and should be continued
C) Only saxagliptin is problematic; pioglitazone is safe and should be continued
D) All three agents are safe in heart failure and no change is needed
E) Metformin is the dangerous agent in heart failure and should be the one stopped
ANSWER: A
Rationale:
Both saxagliptin and pioglitazone are harmful in this setting: saxagliptin increased heart failure hospitalization, and pioglitazone causes sodium and water retention and is contraindicated in NYHA class III-IV heart failure. Both should be replaced, ideally with an SGLT-2 inhibitor that benefits heart failure with reduced ejection fraction, while metformin may continue if renal function permits.
Option B: Option B is incorrect because saxagliptin is also problematic, not safe.
Option C: Option C is incorrect because pioglitazone is also problematic, not safe.
Option D: Option D is incorrect because two of the three agents are harmful in heart failure.
Option E: Option E is incorrect because metformin is not the heart-failure-harmful agent; saxagliptin and pioglitazone are.
8. A patient with T2DM on chronic dapagliflozin is admitted with acute decompensated heart failure and is kept fasting and fluid-restricted; an intravenous insulin infusion is started. Integrating the inpatient pharmacology principles, which management plan is correct?
A) Continue dapagliflozin and target a tight glucose of 4.0 to 6.0 mmol/L (70 to 110 mg per deciliter) with the insulin infusion
B) Continue dapagliflozin and avoid insulin entirely to prevent sodium retention
C) Hold dapagliflozin but target a tight glucose of 4.0 to 6.0 mmol/L (70 to 110 mg per deciliter) with the insulin infusion
D) Hold dapagliflozin during the hospitalization to avoid euglycemic diabetic ketoacidosis in the fasting state, and target an inpatient glucose of 7.8 to 10.0 mmol/L (140 to 180 mg per deciliter) while avoiding hypoglycemia
E) Stop the insulin infusion and resume dapagliflozin immediately to drive decongestion
ANSWER: D
Rationale:
SGLT-2 inhibitors should be held during acute decompensated heart failure because the fasting, fluid-restricted state raises the risk of euglycemic diabetic ketoacidosis, and the recommended inpatient glucose target is 7.8 to 10.0 mmol/L (140 to 180 mg per deciliter) while avoiding hypoglycemia.
Option A: Option A is incorrect because dapagliflozin should be held and the glucose target is not as tight as 70 to 110.
Option B: Option B is incorrect because insulin is the appropriate inpatient agent and should not be avoided.
Option C: Option C is incorrect because, although holding dapagliflozin is right, the glucose target of 70 to 110 is too tight and risks hypoglycemia.
Option E: Option E is incorrect because resuming dapagliflozin in the fasting decompensated state risks euglycemic diabetic ketoacidosis and volume depletion.
9. A patient with T2DM and heart failure requires large daily insulin doses, and the team notes recurrent fluid overload. Integrating the mechanism by which high-dose insulin can aggravate heart failure, which adjustment is most rational?
A) Increase the insulin dose further, since fluid overload reflects inadequate glycemic control
B) Recognize that high-dose insulin promotes sodium retention through renal tubular insulin receptor activation, and transition toward an SGLT-2 inhibitor-containing regimen that partially offsets insulin-mediated sodium retention while allowing insulin dose reduction
C) Add a thiazolidinedione to improve insulin sensitivity and reduce the insulin requirement
D) Add a long-acting sulfonylurea so the insulin dose can be lowered
E) Switch entirely to a DPP-4 inhibitor as monotherapy to eliminate the insulin requirement
ANSWER: B
Rationale:
High-dose insulin promotes sodium retention through renal tubular insulin receptor activation, which can worsen fluid overload in heart failure; transitioning toward an SGLT-2 inhibitor-containing regimen partially offsets this sodium retention and allows the insulin dose to be reduced.
Option A: Option A is incorrect because increasing insulin would worsen the sodium-retaining effect.
Option C: Option C is incorrect because thiazolidinediones themselves cause fluid retention and are contraindicated in advanced heart failure.
Option D: Option D is incorrect because adding a sulfonylurea introduces hypoglycemia risk without addressing the sodium-retention mechanism.
Option E: Option E is incorrect because a DPP-4 inhibitor alone is unlikely to control glycemia in an insulin-requiring patient and does not address the fluid problem.
10. A 32-year-old woman with pre-existing T2DM managed on metformin, empagliflozin, and semaglutide reports a positive pregnancy test. Integrating the pregnancy safety status of each agent, which immediate management plan is correct?
A) Continue all three agents through the first trimester and reassess at 20 weeks
B) Stop only empagliflozin; continue metformin and semaglutide throughout pregnancy
C) Stop empagliflozin and semaglutide now and initiate insulin as the standard of care; metformin may be used only if insulin cannot be used, and is not first-line
D) Continue semaglutide and empagliflozin but stop metformin because it crosses the placenta
E) Replace all agents with a sulfonylurea, which is the preferred oral agent in pregnancy
ANSWER: C
Rationale:
In pregnancy, the SGLT-2 inhibitor (empagliflozin) and GLP-1R agonist (semaglutide) should be stopped because they are contraindicated or not recommended, and insulin should be initiated as the standard of care; metformin crosses the placenta and is used only when insulin cannot be used, so it is not first-line.
Option A: Option A is incorrect because empagliflozin and semaglutide must be stopped at recognition of pregnancy, not continued.
Option B: Option B is incorrect because semaglutide must also be stopped and insulin started.
Option D: Option D is incorrect because semaglutide and empagliflozin are the agents that must be stopped, not metformin alone.
Option E: Option E is incorrect because sulfonylureas are not the preferred agent in pregnancy; insulin is the standard of care.
11. A woman with pre-existing T2DM managed on insulin during pregnancy has just delivered and intends to breastfeed. Integrating the postpartum physiologic change with breastfeeding-compatible pharmacology, which plan is correct?
A) Maintain the third-trimester insulin dose unchanged and avoid all oral agents permanently during breastfeeding
B) Increase the insulin dose at delivery because lactation raises glucose demand, and start an SGLT-2 inhibitor
C) Keep the insulin dose unchanged and start semaglutide, which is preferred during breastfeeding
D) Stop insulin entirely at delivery and start a long-acting sulfonylurea for convenience
E) Reduce the insulin dose substantially at delivery because requirements fall sharply once the placenta is delivered, and if an oral agent is later needed, metformin is considered compatible with breastfeeding whereas most other oral agents have insufficient data
ANSWER: E
Rationale:
Insulin requirements fall sharply within hours of placental delivery, so the dose must be reduced substantially to avoid postpartum hypoglycemia; if an oral agent is later needed, metformin is considered compatible with breastfeeding while most other oral agents have insufficient lactation safety data.
Option A: Option A is incorrect because maintaining the third-trimester dose risks severe hypoglycemia, and metformin is in fact compatible with breastfeeding.
Option B: Option B is incorrect because insulin requirements fall rather than rise after delivery.
Option C: Option C is incorrect because semaglutide is not the preferred breastfeeding agent and insulin requirements still fall.
Option D: Option D is incorrect because abruptly stopping insulin and using a long-acting sulfonylurea introduces hypoglycemia risk and is not the appropriate postpartum transition.
12. An 84-year-old frail man with T2DM has chronic kidney disease (eGFR 34 mL per minute per 1.73 m squared) and heart failure with reduced ejection fraction. He has had two recent hypoglycemic episodes on glimepiride. Integrating his comorbidities with the geriatric priority of hypoglycemia avoidance, which adjustment best serves this patient?
A) Increase glimepiride to improve control and accept the hypoglycemia risk given his comorbidities
B) Add a long-acting sulfonylurea to glimepiride for tighter control
C) Switch to high-dose insulin aiming for an HbA1c below 6.5%
D) Stop glimepiride to eliminate the hypoglycemia source, and favor an SGLT-2 inhibitor that is usable at this eGFR and benefits both his heart failure and kidney disease, accepting a less stringent HbA1c target appropriate to his frailty
E) Add pioglitazone for its insulin-sensitizing effect and low hypoglycemia risk
ANSWER: D
Rationale:
In a frail elderly patient with recurrent hypoglycemia, the sulfonylurea (glimepiride) should be stopped to remove the hypoglycemia source; an SGLT-2 inhibitor is favored because it is usable at this eGFR and provides benefit for both heart failure and diabetic kidney disease, and a less stringent HbA1c target is appropriate to his frailty.
Option A: Option A is incorrect because increasing glimepiride worsens the hypoglycemia that is harming him.
Option B: Option B is incorrect because adding another sulfonylurea compounds hypoglycemia risk.
Option C: Option C is incorrect because a sub-6.5% target with high-dose insulin maximizes hypoglycemia risk in a frail elderly patient.
Option E: Option E is incorrect because pioglitazone causes fluid retention and is contraindicated in heart failure with reduced ejection fraction despite its low hypoglycemia risk.
13. An 88-year-old woman with advanced dementia, declining food intake, and weight loss is on basal insulin, a sulfonylurea, and metformin; her care goals have shifted toward comfort and avoidance of treatment burden. Applying deprescribing principles for advanced geriatric diabetes, which action is the most appropriate initial step?
A) Stop the long-acting sulfonylurea first, since it is the highest hypoglycemia-risk agent in a patient with declining intake, and relax the glycemic target toward symptom avoidance rather than tight control
B) Stop metformin first and intensify the sulfonylurea to maintain tight glycemic control
C) Increase basal insulin to compensate for the reduced food intake
D) Make no changes, since deprescribing is inappropriate in diabetes
E) Add a GLP-1R agonist to suppress appetite further and simplify the regimen
ANSWER: A
Rationale:
In advanced geriatric diabetes with shifting goals of care, the long-acting sulfonylurea should be deprescribed first because it carries the highest hypoglycemia risk, a danger magnified by declining food intake, and the glycemic target should be relaxed toward symptom avoidance rather than tight control.
Option B: Option B is incorrect because intensifying the sulfonylurea increases hypoglycemia risk in a patient with poor intake.
Option C: Option C is incorrect because increasing basal insulin in the setting of reduced intake raises hypoglycemia risk.
Option D: Option D is incorrect because deprescribing is a central skill in advanced geriatric diabetes when the harm-benefit balance has shifted.
Option E: Option E is incorrect because further appetite suppression with a GLP-1R agonist is harmful in a patient already losing weight with poor intake.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.